Vanflyta

Overview

quizartinib

kinase inhibitor

• CYP3A4 substrate
• immunosuppressive oncologic agent
• myelosuppressive oncologic agent
• prolongs QT interval (known)

Contraindicated

• BCG live intravesical
Vanflyta (quizartinib)

+

BCG live intravesical

1 interaction

Contraindicated

quizartinib + BCG live intravesical

contraindicated: combo may incr. risk of disseminated BCG infection; may decr. immune response (immunosuppressive effects)

• cisapride
Vanflyta (quizartinib)

+

cisapride

1 interaction

Contraindicated

quizartinib + cisapride

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Vanflyta (quizartinib)

+

domperidone

1 interaction

Contraindicated

quizartinib + domperidone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Vanflyta (quizartinib)

+

dronedarone

1 interaction

Contraindicated

quizartinib + dronedarone

contraindicated: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• levoketoconazole
Vanflyta (quizartinib)

+

levoketoconazole

1 interaction

Contraindicated

quizartinib + levoketoconazole

contraindicated: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• pimozide
Vanflyta (quizartinib)

+

pimozide

1 interaction

Contraindicated

quizartinib + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• posaconazole
Vanflyta (quizartinib)

+

posaconazole

1 interaction

Contraindicated

quizartinib + posaconazole

contraindicated: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• talimogene laherparepvec
Vanflyta (quizartinib)

+

talimogene laherparepvec

1 interaction

Contraindicated

quizartinib + talimogene laherparepvec

contraindicated: combo may incr. risk of disseminated herpetic infection; may decr. immune response (immunosuppressive effects)

• thioridazine
Vanflyta (quizartinib)

+

thioridazine

1 interaction

Contraindicated

quizartinib + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• adagrasib
Vanflyta (quizartinib)

+

adagrasib

1 interaction

Avoid/Use Alternative

quizartinib + adagrasib

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• albuterol
Vanflyta (quizartinib)

+

albuterol

1 interaction

Avoid/Use Alternative

quizartinib + albuterol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Vanflyta (quizartinib)

+

albuterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + albuterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alfuzosin
Vanflyta (quizartinib)

+

alfuzosin

1 interaction

Avoid/Use Alternative

quizartinib + alfuzosin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amiodarone
Vanflyta (quizartinib)

+

amiodarone

1 interaction

Avoid/Use Alternative

quizartinib + amiodarone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amisulpride
Vanflyta (quizartinib)

+

amisulpride

1 interaction

Avoid/Use Alternative

quizartinib + amisulpride

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Vanflyta (quizartinib)

+

amitriptyline

1 interaction

Avoid/Use Alternative

quizartinib + amitriptyline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anagrelide
Vanflyta (quizartinib)

+

anagrelide

1 interaction

Avoid/Use Alternative

quizartinib + anagrelide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Vanflyta (quizartinib)

+

apalutamide

1 interaction

Avoid/Use Alternative

quizartinib + apalutamide

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• apomorphine
Vanflyta (quizartinib)

+

apomorphine

1 interaction

Avoid/Use Alternative

quizartinib + apomorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arformoterol inhaled
Vanflyta (quizartinib)

+

arformoterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + arformoterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• arsenic trioxide
Vanflyta (quizartinib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

quizartinib + arsenic trioxide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Vanflyta (quizartinib)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

quizartinib + artemether/ lumefantrine

use alternative or monitor ECG, electrolytes: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• asciminib
Vanflyta (quizartinib)

+

asciminib

1 interaction

Avoid/Use Alternative

quizartinib + asciminib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Vanflyta (quizartinib)

+

asenapine

1 interaction

Avoid/Use Alternative

quizartinib + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• atazanavir
Vanflyta (quizartinib)

+

atazanavir

1 interaction

Avoid/Use Alternative

quizartinib + atazanavir

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• azithromycin
Vanflyta (quizartinib)

+

azithromycin

1 interaction

Avoid/Use Alternative

quizartinib + azithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Vanflyta (quizartinib)

+

bedaquiline

1 interaction

Avoid/Use Alternative

quizartinib + bedaquiline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• berotralstat
Vanflyta (quizartinib)

+

berotralstat

1 interaction

Avoid/Use Alternative

quizartinib + berotralstat

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• bosentan
Vanflyta (quizartinib)

+

bosentan

1 interaction

Avoid/Use Alternative

quizartinib + bosentan

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• buprenorphine
Vanflyta (quizartinib)

+

buprenorphine

1 interaction

Avoid/Use Alternative

quizartinib + buprenorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• butalbital
Vanflyta (quizartinib)

+

butalbital

1 interaction

Avoid/Use Alternative

quizartinib + butalbital

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• cabozantinib
Vanflyta (quizartinib)

+

cabozantinib

1 interaction

Avoid/Use Alternative

quizartinib + cabozantinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• carbamazepine
Vanflyta (quizartinib)

+

carbamazepine

1 interaction

Avoid/Use Alternative

quizartinib + carbamazepine

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• cenobamate
Vanflyta (quizartinib)

+

cenobamate

1 interaction

Avoid/Use Alternative

quizartinib + cenobamate

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• ceritinib
Vanflyta (quizartinib)

+

ceritinib

1 interaction

Avoid/Use Alternative

quizartinib + ceritinib

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• chloramphenicol
Vanflyta (quizartinib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

quizartinib + chloramphenicol

monitor ECG, electrolytes, CBC and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• chloroquine
Vanflyta (quizartinib)

+

chloroquine

1 interaction

Avoid/Use Alternative

quizartinib + chloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Vanflyta (quizartinib)

+

chlorpromazine

1 interaction

Avoid/Use Alternative

quizartinib + chlorpromazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ciprofloxacin
Vanflyta (quizartinib)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

quizartinib + ciprofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• citalopram
Vanflyta (quizartinib)

+

citalopram

1 interaction

Avoid/Use Alternative

quizartinib + citalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cladribine oral
Vanflyta (quizartinib)

+

cladribine oral

1 interaction

Avoid/Use Alternative

quizartinib + cladribine oral

use alternative or monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• clarithromycin
Vanflyta (quizartinib)

+

clarithromycin

1 interaction

Avoid/Use Alternative

quizartinib + clarithromycin

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• clofazimine
Vanflyta (quizartinib)

+

clofazimine

1 interaction

Avoid/Use Alternative

quizartinib + clofazimine

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• clomipramine
Vanflyta (quizartinib)

+

clomipramine

1 interaction

Avoid/Use Alternative

quizartinib + clomipramine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clozapine
Vanflyta (quizartinib)

+

clozapine

1 interaction

Avoid/Use Alternative

quizartinib + clozapine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• cobicistat
Vanflyta (quizartinib)

+

cobicistat

1 interaction

Avoid/Use Alternative

quizartinib + cobicistat

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• crizotinib
Vanflyta (quizartinib)

+

crizotinib

1 interaction

Avoid/Use Alternative

quizartinib + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dabrafenib
Vanflyta (quizartinib)

+

dabrafenib

1 interaction

Avoid/Use Alternative

quizartinib + dabrafenib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• dasatinib
Vanflyta (quizartinib)

+

dasatinib

1 interaction

Avoid/Use Alternative

quizartinib + dasatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• deferiprone
Vanflyta (quizartinib)

+

deferiprone

1 interaction

Avoid/Use Alternative

quizartinib + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• degarelix
Vanflyta (quizartinib)

+

degarelix

1 interaction

Avoid/Use Alternative

quizartinib + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Vanflyta (quizartinib)

+

desflurane

1 interaction

Avoid/Use Alternative

quizartinib + desflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Vanflyta (quizartinib)

+

desipramine

1 interaction

Avoid/Use Alternative

quizartinib + desipramine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• deutetrabenazine
Vanflyta (quizartinib)

+

deutetrabenazine

1 interaction

Avoid/Use Alternative

quizartinib + deutetrabenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine
Vanflyta (quizartinib)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

quizartinib + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Vanflyta (quizartinib)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

quizartinib + dexmedetomidine injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexrazoxane
Vanflyta (quizartinib)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

quizartinib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemotx (additive effects; mechanism unknown)

• disopyramide
Vanflyta (quizartinib)

+

disopyramide

1 interaction

Avoid/Use Alternative

quizartinib + disopyramide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dofetilide
Vanflyta (quizartinib)

+

dofetilide

1 interaction

Avoid/Use Alternative

quizartinib + dofetilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Vanflyta (quizartinib)

+

donepezil

1 interaction

Avoid/Use Alternative

quizartinib + donepezil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• droperidol
Vanflyta (quizartinib)

+

droperidol

1 interaction

Avoid/Use Alternative

quizartinib + droperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Vanflyta (quizartinib)

+

efavirenz

1 interaction

Avoid/Use Alternative

quizartinib + efavirenz

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• eliglustat
Vanflyta (quizartinib)

+

eliglustat

1 interaction

Avoid/Use Alternative

quizartinib + eliglustat

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• encorafenib
Vanflyta (quizartinib)

+

encorafenib

1 interaction

Avoid/Use Alternative

quizartinib + encorafenib

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• entrectinib
Vanflyta (quizartinib)

+

entrectinib

1 interaction

Avoid/Use Alternative

quizartinib + entrectinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• enzalutamide
Vanflyta (quizartinib)

+

enzalutamide

1 interaction

Avoid/Use Alternative

quizartinib + enzalutamide

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• ephedra
Vanflyta (quizartinib)

+

ephedra

1 interaction

Avoid/Use Alternative

quizartinib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Vanflyta (quizartinib)

+

epirubicin

1 interaction

Avoid/Use Alternative

quizartinib + epirubicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Vanflyta (quizartinib)

+

eribulin

1 interaction

Avoid/Use Alternative

quizartinib + eribulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Vanflyta (quizartinib)

+

erythromycin

1 interaction

Avoid/Use Alternative

quizartinib + erythromycin

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• escitalopram
Vanflyta (quizartinib)

+

escitalopram

1 interaction

Avoid/Use Alternative

quizartinib + escitalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• etrasimod
Vanflyta (quizartinib)

+

etrasimod

1 interaction

Avoid/Use Alternative

quizartinib + etrasimod

avoid combo during and x5wk after etrasimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• etravirine
Vanflyta (quizartinib)

+

etravirine

1 interaction

Avoid/Use Alternative

quizartinib + etravirine

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• fexinidazole
Vanflyta (quizartinib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

quizartinib + fexinidazole

avoid combo during and x7 days after fexinidazole tx; if possible, do not initiate fexinidazole until 5 half-lives after quizartinib D/C: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (hepatic metab. induced; additive effects)

• fingolimod
Vanflyta (quizartinib)

+

fingolimod

1 interaction

Avoid/Use Alternative

quizartinib + fingolimod

use alternative or monitor ECG, electrolytes; caution advised during and x2mo after fingolimod tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• flecainide
Vanflyta (quizartinib)

+

flecainide

1 interaction

Avoid/Use Alternative

quizartinib + flecainide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Vanflyta (quizartinib)

+

fluconazole

1 interaction

Avoid/Use Alternative

quizartinib + fluconazole

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• fluorouracil
Vanflyta (quizartinib)

+

fluorouracil

1 interaction

Avoid/Use Alternative

quizartinib + fluorouracil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Vanflyta (quizartinib)

+

fluoxetine

1 interaction

Avoid/Use Alternative

quizartinib + fluoxetine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• formoterol inhaled
Vanflyta (quizartinib)

+

formoterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + formoterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• foscarnet
Vanflyta (quizartinib)

+

foscarnet

1 interaction

Avoid/Use Alternative

quizartinib + foscarnet

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• fosphenytoin
Vanflyta (quizartinib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

quizartinib + fosphenytoin

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• fostemsavir
Vanflyta (quizartinib)

+

fostemsavir

1 interaction

Avoid/Use Alternative

quizartinib + fostemsavir

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ganciclovir
Vanflyta (quizartinib)

+

ganciclovir

1 interaction

Avoid/Use Alternative

quizartinib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gemtuzumab ozogamicin
Vanflyta (quizartinib)

+

gemtuzumab ozogamicin

1 interaction

Avoid/Use Alternative

quizartinib + gemtuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepirone
Vanflyta (quizartinib)

+

gepirone

1 interaction

Avoid/Use Alternative

quizartinib + gepirone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepotidacin
Vanflyta (quizartinib)

+

gepotidacin

1 interaction

Avoid/Use Alternative

quizartinib + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Vanflyta (quizartinib)

+

gilteritinib

1 interaction

Avoid/Use Alternative

quizartinib + gilteritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• givinostat
Vanflyta (quizartinib)

+

givinostat

1 interaction

Avoid/Use Alternative

quizartinib + givinostat

use alternative or monitor CBC, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• glasdegib
Vanflyta (quizartinib)

+

glasdegib

1 interaction

Avoid/Use Alternative

quizartinib + glasdegib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Vanflyta (quizartinib)

+

goserelin

1 interaction

Avoid/Use Alternative

quizartinib + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• granisetron
Vanflyta (quizartinib)

+

granisetron

1 interaction

Avoid/Use Alternative

quizartinib + granisetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• grapefruit
Vanflyta (quizartinib)

+

grapefruit

1 interaction

Avoid/Use Alternative

quizartinib + grapefruit

use alternative or monitor ECG, electrolytes, especially w/ large amounts of grapefruit (>1L juice): combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metab. inhibited, additive effects)

• haloperidol
Vanflyta (quizartinib)

+

haloperidol

1 interaction

Avoid/Use Alternative

quizartinib + haloperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Vanflyta (quizartinib)

+

histrelin

1 interaction

Avoid/Use Alternative

quizartinib + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Vanflyta (quizartinib)

+

hydrocodone

1 interaction

Avoid/Use Alternative

quizartinib + hydrocodone

use alternative or monitor ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxychloroquine
Vanflyta (quizartinib)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

quizartinib + hydroxychloroquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• hydroxyzine
Vanflyta (quizartinib)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

quizartinib + hydroxyzine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Vanflyta (quizartinib)

+

ibutilide

1 interaction

Avoid/Use Alternative

quizartinib + ibutilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Vanflyta (quizartinib)

+

idelalisib

1 interaction

Avoid/Use Alternative

quizartinib + idelalisib

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• iloperidone
Vanflyta (quizartinib)

+

iloperidone

1 interaction

Avoid/Use Alternative

quizartinib + iloperidone

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• inotuzumab ozogamicin
Vanflyta (quizartinib)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

quizartinib + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoflurane
Vanflyta (quizartinib)

+

isoflurane

1 interaction

Avoid/Use Alternative

quizartinib + isoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• itraconazole
Vanflyta (quizartinib)

+

itraconazole

1 interaction

Avoid/Use Alternative

quizartinib + itraconazole

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• ivabradine
Vanflyta (quizartinib)

+

ivabradine

1 interaction

Avoid/Use Alternative

quizartinib + ivabradine

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ivosidenib
Vanflyta (quizartinib)

+

ivosidenib

1 interaction

Avoid/Use Alternative

quizartinib + ivosidenib

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• ketoconazole
Vanflyta (quizartinib)

+

ketoconazole

1 interaction

Avoid/Use Alternative

quizartinib + ketoconazole

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• lapatinib
Vanflyta (quizartinib)

+

lapatinib

1 interaction

Avoid/Use Alternative

quizartinib + lapatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lefamulin
Vanflyta (quizartinib)

+

lefamulin

1 interaction

Avoid/Use Alternative

quizartinib + lefamulin

use alternative or monitor ECG, electrolytes: combo w/ oral lefamulin may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo w/ IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, additive effects)

• lenvatinib
Vanflyta (quizartinib)

+

lenvatinib

1 interaction

Avoid/Use Alternative

quizartinib + lenvatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• leuprolide
Vanflyta (quizartinib)

+

leuprolide

1 interaction

Avoid/Use Alternative

quizartinib + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levalbuterol inhaled
Vanflyta (quizartinib)

+

levalbuterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + levalbuterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levofloxacin
Vanflyta (quizartinib)

+

levofloxacin

1 interaction

Avoid/Use Alternative

quizartinib + levofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lofexidine
Vanflyta (quizartinib)

+

lofexidine

1 interaction

Avoid/Use Alternative

quizartinib + lofexidine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Vanflyta (quizartinib)

+

lonafarnib

1 interaction

Avoid/Use Alternative

quizartinib + lonafarnib

use alternative or monitor HR, ECG, electrolytes, CBC and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• loperamide
Vanflyta (quizartinib)

+

loperamide

1 interaction

Avoid/Use Alternative

quizartinib + loperamide

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Vanflyta (quizartinib)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

quizartinib + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. quizartinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metab. altered, additive effects)

• lorlatinib
Vanflyta (quizartinib)

+

lorlatinib

1 interaction

Avoid/Use Alternative

quizartinib + lorlatinib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• lumacaftor/ivacaftor
Vanflyta (quizartinib)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

quizartinib + lumacaftor/ ivacaftor

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• lumateperone
Vanflyta (quizartinib)

+

lumateperone

1 interaction

Avoid/Use Alternative

quizartinib + lumateperone

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• lurasidone
Vanflyta (quizartinib)

+

lurasidone

1 interaction

Avoid/Use Alternative

quizartinib + lurasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• macimorelin
Vanflyta (quizartinib)

+

macimorelin

1 interaction

Avoid/Use Alternative

quizartinib + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mavacamten
Vanflyta (quizartinib)

+

mavacamten

1 interaction

Avoid/Use Alternative

quizartinib + mavacamten

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• mavorixafor
Vanflyta (quizartinib)

+

mavorixafor

1 interaction

Avoid/Use Alternative

quizartinib + mavorixafor

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mefloquine
Vanflyta (quizartinib)

+

mefloquine

1 interaction

Avoid/Use Alternative

quizartinib + mefloquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• meperidine
Vanflyta (quizartinib)

+

meperidine

1 interaction

Avoid/Use Alternative

quizartinib + meperidine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• methadone
Vanflyta (quizartinib)

+

methadone

1 interaction

Avoid/Use Alternative

quizartinib + methadone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• metronidazole
Vanflyta (quizartinib)

+

metronidazole

1 interaction

Avoid/Use Alternative

quizartinib + metronidazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midostaurin
Vanflyta (quizartinib)

+

midostaurin

1 interaction

Avoid/Use Alternative

quizartinib + midostaurin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mifepristone
Vanflyta (quizartinib)

+

mifepristone

1 interaction

Avoid/Use Alternative

quizartinib + mifepristone

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows during and x14 days after daily mifepristone use: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; ; avoid combo if on quizartinib 17.7 mg qd; caution advised if pregnancy termination use: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mirtazapine
Vanflyta (quizartinib)

+

mirtazapine

1 interaction

Avoid/Use Alternative

quizartinib + mirtazapine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mitapivat
Vanflyta (quizartinib)

+

mitapivat

1 interaction

Avoid/Use Alternative

quizartinib + mitapivat

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• mitotane
Vanflyta (quizartinib)

+

mitotane

1 interaction

Avoid/Use Alternative

quizartinib + mitotane

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• mobocertinib
Vanflyta (quizartinib)

+

mobocertinib

1 interaction

Avoid/Use Alternative

quizartinib + mobocertinib

use alternative or monitor ECG, electrolytes: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• modafinil
Vanflyta (quizartinib)

+

modafinil

1 interaction

Avoid/Use Alternative

quizartinib + modafinil

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• moxifloxacin
Vanflyta (quizartinib)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

quizartinib + moxifloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nafcillin
Vanflyta (quizartinib)

+

nafcillin

1 interaction

Avoid/Use Alternative

quizartinib + nafcillin

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• nefazodone
Vanflyta (quizartinib)

+

nefazodone

1 interaction

Avoid/Use Alternative

quizartinib + nefazodone

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• nelfinavir
Vanflyta (quizartinib)

+

nelfinavir

1 interaction

Avoid/Use Alternative

quizartinib + nelfinavir

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• nilotinib
Vanflyta (quizartinib)

+

nilotinib

1 interaction

Avoid/Use Alternative

quizartinib + nilotinib

avoid combo: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ofloxacin
Vanflyta (quizartinib)

+

ofloxacin

1 interaction

Avoid/Use Alternative

quizartinib + ofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oliceridine
Vanflyta (quizartinib)

+

oliceridine

1 interaction

Avoid/Use Alternative

quizartinib + oliceridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Vanflyta (quizartinib)

+

olodaterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + olodaterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ondansetron
Vanflyta (quizartinib)

+

ondansetron

1 interaction

Avoid/Use Alternative

quizartinib + ondansetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osilodrostat
Vanflyta (quizartinib)

+

osilodrostat

1 interaction

Avoid/Use Alternative

quizartinib + osilodrostat

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Vanflyta (quizartinib)

+

osimertinib

1 interaction

Avoid/Use Alternative

quizartinib + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Vanflyta (quizartinib)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

quizartinib + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ozanimod
Vanflyta (quizartinib)

+

ozanimod

1 interaction

Avoid/Use Alternative

quizartinib + ozanimod

use alternative or monitor ECG, electrolytes; caution advised during and x3mo after ozanimod tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• pacritinib
Vanflyta (quizartinib)

+

pacritinib

1 interaction

Avoid/Use Alternative

quizartinib + pacritinib

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• palifermin
Vanflyta (quizartinib)

+

palifermin

1 interaction

Avoid/Use Alternative

quizartinib + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• paliperidone
Vanflyta (quizartinib)

+

paliperidone

1 interaction

Avoid/Use Alternative

quizartinib + paliperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Vanflyta (quizartinib)

+

palonosetron

1 interaction

Avoid/Use Alternative

quizartinib + palonosetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• panobinostat
Vanflyta (quizartinib)

+

panobinostat

1 interaction

Avoid/Use Alternative

quizartinib + panobinostat

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Vanflyta (quizartinib)

+

pasireotide

1 interaction

Avoid/Use Alternative

quizartinib + pasireotide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Vanflyta (quizartinib)

+

pazopanib

1 interaction

Avoid/Use Alternative

quizartinib + pazopanib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• penicillamine
Vanflyta (quizartinib)

+

penicillamine

1 interaction

Avoid/Use Alternative

quizartinib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Vanflyta (quizartinib)

+

pentamidine

1 interaction

Avoid/Use Alternative

quizartinib + pentamidine

use alternative or monitor ECG, electrolytes, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• pentobarbital
Vanflyta (quizartinib)

+

pentobarbital

1 interaction

Avoid/Use Alternative

quizartinib + pentobarbital

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• pexidartinib
Vanflyta (quizartinib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

quizartinib + pexidartinib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• phenobarbital
Vanflyta (quizartinib)

+

phenobarbital

1 interaction

Avoid/Use Alternative

quizartinib + phenobarbital

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• phenytoin
Vanflyta (quizartinib)

+

phenytoin

1 interaction

Avoid/Use Alternative

quizartinib + phenytoin

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• pimavanserin
Vanflyta (quizartinib)

+

pimavanserin

1 interaction

Avoid/Use Alternative

quizartinib + pimavanserin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pimecrolimus topical
Vanflyta (quizartinib)

+

pimecrolimus topical

1 interaction

Avoid/Use Alternative

quizartinib + pimecrolimus topical

avoid combo: combo may incr. risk of serious infection (additive effects)

• pitolisant
Vanflyta (quizartinib)

+

pitolisant

1 interaction

Avoid/Use Alternative

quizartinib + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Vanflyta (quizartinib)

+

ponesimod

1 interaction

Avoid/Use Alternative

quizartinib + ponesimod

use alternative or monitor HR, ECG, electrolytes; caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• pralsetinib
Vanflyta (quizartinib)

+

pralsetinib

1 interaction

Avoid/Use Alternative

quizartinib + pralsetinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• primaquine
Vanflyta (quizartinib)

+

primaquine

1 interaction

Avoid/Use Alternative

quizartinib + primaquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• primidone
Vanflyta (quizartinib)

+

primidone

1 interaction

Avoid/Use Alternative

quizartinib + primidone

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• procainamide
Vanflyta (quizartinib)

+

procainamide

1 interaction

Avoid/Use Alternative

quizartinib + procainamide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• promethazine
Vanflyta (quizartinib)

+

promethazine

1 interaction

Avoid/Use Alternative

quizartinib + promethazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Vanflyta (quizartinib)

+

propafenone

1 interaction

Avoid/Use Alternative

quizartinib + propafenone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quetiapine
Vanflyta (quizartinib)

+

quetiapine

1 interaction

Avoid/Use Alternative

quizartinib + quetiapine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (antiarrhythmic)
Vanflyta (quizartinib)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

quizartinib + quinidine (antiarrhythmic)

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Vanflyta (quizartinib)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

quizartinib + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Vanflyta (quizartinib)

+

quinine

1 interaction

Avoid/Use Alternative

quizartinib + quinine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• radium Ra 223 dichloride
Vanflyta (quizartinib)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

quizartinib + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ranolazine
Vanflyta (quizartinib)

+

ranolazine

1 interaction

Avoid/Use Alternative

quizartinib + ranolazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• relugolix
Vanflyta (quizartinib)

+

relugolix

1 interaction

Avoid/Use Alternative

quizartinib + relugolix

use alternative or monitor ECG, electrolytes if prostate cancer use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• repotrectinib
Vanflyta (quizartinib)

+

repotrectinib

1 interaction

Avoid/Use Alternative

quizartinib + repotrectinib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• revumenib
Vanflyta (quizartinib)

+

revumenib

1 interaction

Avoid/Use Alternative

quizartinib + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Vanflyta (quizartinib)

+

ribociclib

1 interaction

Avoid/Use Alternative

quizartinib + ribociclib

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• rifabutin
Vanflyta (quizartinib)

+

rifabutin

1 interaction

Avoid/Use Alternative

quizartinib + rifabutin

avoid combo: combo may decr. quizartinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. induced; additive effects)

• rifampin
Vanflyta (quizartinib)

+

rifampin

1 interaction

Avoid/Use Alternative

quizartinib + rifampin

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• rifapentine
Vanflyta (quizartinib)

+

rifapentine

1 interaction

Avoid/Use Alternative

quizartinib + rifapentine

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• rilpivirine
Vanflyta (quizartinib)

+

rilpivirine

1 interaction

Avoid/Use Alternative

quizartinib + rilpivirine

use alternative or monitor ECG, electrolytes; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ritonavir
Vanflyta (quizartinib)

+

ritonavir

1 interaction

Avoid/Use Alternative

quizartinib + ritonavir

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• romidepsin
Vanflyta (quizartinib)

+

romidepsin

1 interaction

Avoid/Use Alternative

quizartinib + romidepsin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ropeginterferon alfa-2b
Vanflyta (quizartinib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

quizartinib + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• rucaparib
Vanflyta (quizartinib)

+

rucaparib

1 interaction

Avoid/Use Alternative

quizartinib + rucaparib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sacituzumab govitecan
Vanflyta (quizartinib)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

quizartinib + sacituzumab govitecan

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• salmeterol inhaled
Vanflyta (quizartinib)

+

salmeterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + salmeterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Vanflyta (quizartinib)

+

selpercatinib

1 interaction

Avoid/Use Alternative

quizartinib + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sertraline
Vanflyta (quizartinib)

+

sertraline

1 interaction

Avoid/Use Alternative

quizartinib + sertraline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sevoflurane
Vanflyta (quizartinib)

+

sevoflurane

1 interaction

Avoid/Use Alternative

quizartinib + sevoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• siponimod
Vanflyta (quizartinib)

+

siponimod

1 interaction

Avoid/Use Alternative

quizartinib + siponimod

use alternative or monitor HR, ECG, electrolytes; caution advised during and x3-4wk after siponimod tx: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, serious infection; infection risk may be prolonged (additive effects)

• solifenacin
Vanflyta (quizartinib)

+

solifenacin

1 interaction

Avoid/Use Alternative

quizartinib + solifenacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sorafenib
Vanflyta (quizartinib)

+

sorafenib

1 interaction

Avoid/Use Alternative

quizartinib + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Vanflyta (quizartinib)

+

sotalol

1 interaction

Avoid/Use Alternative

quizartinib + sotalol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotorasib
Vanflyta (quizartinib)

+

sotorasib

1 interaction

Avoid/Use Alternative

quizartinib + sotorasib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• St. John's wort
Vanflyta (quizartinib)

+

St. John's wort

1 interaction

Avoid/Use Alternative

quizartinib + St. John's wort

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• sunitinib
Vanflyta (quizartinib)

+

sunitinib

1 interaction

Avoid/Use Alternative

quizartinib + sunitinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tacrolimus
Vanflyta (quizartinib)

+

tacrolimus

1 interaction

Avoid/Use Alternative

quizartinib + tacrolimus

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, serious infection (additive effects)

• tazemetostat
Vanflyta (quizartinib)

+

tazemetostat

1 interaction

Avoid/Use Alternative

quizartinib + tazemetostat

use alternative or monitor ECG, electrolytes: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• telavancin
Vanflyta (quizartinib)

+

telavancin

1 interaction

Avoid/Use Alternative

quizartinib + telavancin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• terbutaline
Vanflyta (quizartinib)

+

terbutaline

1 interaction

Avoid/Use Alternative

quizartinib + terbutaline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tetrabenazine
Vanflyta (quizartinib)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

quizartinib + tetrabenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tipranavir
Vanflyta (quizartinib)

+

tipranavir

1 interaction

Avoid/Use Alternative

quizartinib + tipranavir

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• tolterodine
Vanflyta (quizartinib)

+

tolterodine

1 interaction

Avoid/Use Alternative

quizartinib + tolterodine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• toremifene
Vanflyta (quizartinib)

+

toremifene

1 interaction

Avoid/Use Alternative

quizartinib + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Vanflyta (quizartinib)

+

tramadol

1 interaction

Avoid/Use Alternative

quizartinib + tramadol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trazodone
Vanflyta (quizartinib)

+

trazodone

1 interaction

Avoid/Use Alternative

quizartinib + trazodone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triclabendazole
Vanflyta (quizartinib)

+

triclabendazole

1 interaction

Avoid/Use Alternative

quizartinib + triclabendazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Vanflyta (quizartinib)

+

trifluridine

1 interaction

Avoid/Use Alternative

quizartinib + trifluridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Vanflyta (quizartinib)

+

triptorelin

1 interaction

Avoid/Use Alternative

quizartinib + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tucatinib
Vanflyta (quizartinib)

+

tucatinib

1 interaction

Avoid/Use Alternative

quizartinib + tucatinib

monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• valbenazine
Vanflyta (quizartinib)

+

valbenazine

1 interaction

Avoid/Use Alternative

quizartinib + valbenazine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valganciclovir
Vanflyta (quizartinib)

+

valganciclovir

1 interaction

Avoid/Use Alternative

quizartinib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Vanflyta (quizartinib)

+

vandetanib

1 interaction

Avoid/Use Alternative

quizartinib + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vardenafil
Vanflyta (quizartinib)

+

vardenafil

1 interaction

Avoid/Use Alternative

quizartinib + vardenafil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Vanflyta (quizartinib)

+

vemurafenib

1 interaction

Avoid/Use Alternative

quizartinib + vemurafenib

use alternative or monitor ECG, electrolytes: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• venlafaxine
Vanflyta (quizartinib)

+

venlafaxine

1 interaction

Avoid/Use Alternative

quizartinib + venlafaxine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vilanterol inhaled
Vanflyta (quizartinib)

+

vilanterol inhaled

1 interaction

Avoid/Use Alternative

quizartinib + vilanterol inhaled

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voclosporin
Vanflyta (quizartinib)

+

voclosporin

1 interaction

Avoid/Use Alternative

quizartinib + voclosporin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, serious infection (additive effects)

• voriconazole
Vanflyta (quizartinib)

+

voriconazole

1 interaction

Avoid/Use Alternative

quizartinib + voriconazole

use alternative or monitor ECG, electrolytes and adjust quizartinib dose as follows: if on quizartinib 53 mg qd, decr. to 26.5 mg qd; if on quizartinib 35.4 mg qd, decr. to 17.7 mg qd; if on quizartinib 26.5 mg qd, decr. to 17.7 mg qd; avoid combo if on quizartinib 17.7 mg qd: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ziprasidone
Vanflyta (quizartinib)

+

ziprasidone

1 interaction

Avoid/Use Alternative

quizartinib + ziprasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• albendazole
Vanflyta (quizartinib)

+

albendazole

1 interaction

Monitor/Modify Tx

quizartinib + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alemtuzumab
Vanflyta (quizartinib)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

quizartinib + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of serious infection, myelosuppression (additive effects)

• allopurinol
Vanflyta (quizartinib)

+

allopurinol

1 interaction

Monitor/Modify Tx

quizartinib + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• anti-thymocyte globulin
Vanflyta (quizartinib)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

quizartinib + anti-thymocyte globulin

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• aprepitant
Vanflyta (quizartinib)

+

aprepitant

1 interaction

Monitor/Modify Tx

quizartinib + aprepitant

if aprepitant 3-day regimen, monitor ECG, electrolytes; aprepitant single-dose regimen OK: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• atidarsagene autotemcel
Vanflyta (quizartinib)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

quizartinib + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression (additive effects)

• auranofin
Vanflyta (quizartinib)

+

auranofin

1 interaction

Monitor/Modify Tx

quizartinib + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avacopan
Vanflyta (quizartinib)

+

avacopan

1 interaction

Monitor/Modify Tx

quizartinib + avacopan

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• azathioprine
Vanflyta (quizartinib)

+

azathioprine

1 interaction

Monitor/Modify Tx

quizartinib + azathioprine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• balsalazide
Vanflyta (quizartinib)

+

balsalazide

1 interaction

Monitor/Modify Tx

quizartinib + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Vanflyta (quizartinib)

+

baricitinib

1 interaction

Monitor/Modify Tx

quizartinib + baricitinib

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• benznidazole
Vanflyta (quizartinib)

+

benznidazole

1 interaction

Monitor/Modify Tx

quizartinib + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• betibeglogene autotemcel
Vanflyta (quizartinib)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

quizartinib + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• cidofovir
Vanflyta (quizartinib)

+

cidofovir

1 interaction

Monitor/Modify Tx

quizartinib + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• colchicine
Vanflyta (quizartinib)

+

colchicine

1 interaction

Monitor/Modify Tx

quizartinib + colchicine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• conivaptan
Vanflyta (quizartinib)

+

conivaptan

1 interaction

Monitor/Modify Tx

quizartinib + conivaptan

monitor ECG, electrolytes during and x7 days after conivaptan tx: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• cyclophosphamide
Vanflyta (quizartinib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

quizartinib + cyclophosphamide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• cyclosporine
Vanflyta (quizartinib)

+

cyclosporine

1 interaction

Monitor/Modify Tx

quizartinib + cyclosporine

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• danazol
Vanflyta (quizartinib)

+

danazol

1 interaction

Monitor/Modify Tx

quizartinib + danazol

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• dapsone
Vanflyta (quizartinib)

+

dapsone

1 interaction

Monitor/Modify Tx

quizartinib + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• darunavir
Vanflyta (quizartinib)

+

darunavir

1 interaction

Monitor/Modify Tx

quizartinib + darunavir

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• deferasirox
Vanflyta (quizartinib)

+

deferasirox

1 interaction

Monitor/Modify Tx

quizartinib + deferasirox

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deuruxolitinib
Vanflyta (quizartinib)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

quizartinib + deuruxolitinib

monitor CBC: combo may incr. risk of myelosuppression, serious infection (additive effects)

• diltiazem
Vanflyta (quizartinib)

+

diltiazem

1 interaction

Monitor/Modify Tx

quizartinib + diltiazem

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• duvelisib
Vanflyta (quizartinib)

+

duvelisib

1 interaction

Monitor/Modify Tx

quizartinib + duvelisib

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• efbemalenograstim alfa
Vanflyta (quizartinib)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

quizartinib + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Vanflyta (quizartinib)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

quizartinib + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elivaldogene autotemcel
Vanflyta (quizartinib)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

quizartinib + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of serious infection, myelosuppression (additive effects)

• everolimus
Vanflyta (quizartinib)

+

everolimus

1 interaction

Monitor/Modify Tx

quizartinib + everolimus

monitor CBC; admin. PCP prophylaxis: combo may incr. risk of serious infection, myelosuppression (additive effects)

• exagamglogene autotemcel
Vanflyta (quizartinib)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

quizartinib + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• fedratinib
Vanflyta (quizartinib)

+

fedratinib

1 interaction

Monitor/Modify Tx

quizartinib + fedratinib

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• filgrastim (G-CSF)
Vanflyta (quizartinib)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

quizartinib + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• flucytosine
Vanflyta (quizartinib)

+

flucytosine

1 interaction

Monitor/Modify Tx

quizartinib + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluphenazine
Vanflyta (quizartinib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

quizartinib + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fosamprenavir
Vanflyta (quizartinib)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

quizartinib + fosamprenavir

monitor ECG, electrolytes: combo may incr. or decr. quizartinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metab. altered)

• fostamatinib
Vanflyta (quizartinib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

quizartinib + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyurea
Vanflyta (quizartinib)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

quizartinib + hydroxyurea

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• imatinib
Vanflyta (quizartinib)

+

imatinib

1 interaction

Monitor/Modify Tx

quizartinib + imatinib

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• interferon beta 1a
Vanflyta (quizartinib)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

quizartinib + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Vanflyta (quizartinib)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

quizartinib + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Vanflyta (quizartinib)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

quizartinib + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isavuconazonium
Vanflyta (quizartinib)

+

isavuconazonium

1 interaction

Monitor/Modify Tx

quizartinib + isavuconazonium

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• leflunomide
Vanflyta (quizartinib)

+

leflunomide

1 interaction

Monitor/Modify Tx

quizartinib + leflunomide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• lenacapavir
Vanflyta (quizartinib)

+

lenacapavir

1 interaction

Monitor/Modify Tx

quizartinib + lenacapavir

monitor ECG, electrolytes during and x9mo after lenacapavir: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• letermovir
Vanflyta (quizartinib)

+

letermovir

1 interaction

Monitor/Modify Tx

quizartinib + letermovir

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• linezolid
Vanflyta (quizartinib)

+

linezolid

1 interaction

Monitor/Modify Tx

quizartinib + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lovotibeglogene autotemcel
Vanflyta (quizartinib)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

quizartinib + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Vanflyta (quizartinib)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

quizartinib + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mercaptopurine
Vanflyta (quizartinib)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

quizartinib + mercaptopurine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mesalamine
Vanflyta (quizartinib)

+

mesalamine

1 interaction

Monitor/Modify Tx

quizartinib + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Vanflyta (quizartinib)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

quizartinib + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methotrexate
Vanflyta (quizartinib)

+

methotrexate

1 interaction

Monitor/Modify Tx

quizartinib + methotrexate

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mycophenolate mofetil
Vanflyta (quizartinib)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

quizartinib + mycophenolate mofetil

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• mycophenolic acid
Vanflyta (quizartinib)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

quizartinib + mycophenolic acid

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• netupitant
Vanflyta (quizartinib)

+

netupitant

1 interaction

Monitor/Modify Tx

quizartinib + netupitant

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• nirogacestat
Vanflyta (quizartinib)

+

nirogacestat

1 interaction

Monitor/Modify Tx

quizartinib + nirogacestat

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effect (hepatic metab. inhibited)

• olsalazine
Vanflyta (quizartinib)

+

olsalazine

1 interaction

Monitor/Modify Tx

quizartinib + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pegfilgrastim (G-CSF)
Vanflyta (quizartinib)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

quizartinib + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Vanflyta (quizartinib)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

quizartinib + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Vanflyta (quizartinib)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

quizartinib + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• proguanil
Vanflyta (quizartinib)

+

proguanil

1 interaction

Monitor/Modify Tx

quizartinib + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• pyrimethamine
Vanflyta (quizartinib)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

quizartinib + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ribavirin
Vanflyta (quizartinib)

+

ribavirin

1 interaction

Monitor/Modify Tx

quizartinib + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rituximab
Vanflyta (quizartinib)

+

rituximab

1 interaction

Monitor/Modify Tx

quizartinib + rituximab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• ruxolitinib topical
Vanflyta (quizartinib)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

quizartinib + ruxolitinib topical

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• sargramostim (GM-CSF)
Vanflyta (quizartinib)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

quizartinib + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Vanflyta (quizartinib)

+

sarilumab

1 interaction

Monitor/Modify Tx

quizartinib + sarilumab

monitor CBC: combo may decr. quizartinib levels, efficacy; may incr. risk of serious infection, myelosuppression (hepatic metab. altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Vanflyta (quizartinib)

+

satralizumab

1 interaction

Monitor/Modify Tx

quizartinib + satralizumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• sipuleucel-T
Vanflyta (quizartinib)

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

quizartinib + sipuleucel-T

consider decr. quizartinib dose or D/C during leukapheresis and sipuleucel-T admin.: combo may decr. efficacy of sipuleucel-T; may incr. risk of adverse effects (antagonistic effects; additive effects)

• sirolimus
Vanflyta (quizartinib)

+

sirolimus

1 interaction

Monitor/Modify Tx

quizartinib + sirolimus

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• stiripentol
Vanflyta (quizartinib)

+

stiripentol

1 interaction

Monitor/Modify Tx

quizartinib + stiripentol

monitor CBC: combo may decr. quizartinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. possibly induced; additive effects)

• succimer
Vanflyta (quizartinib)

+

succimer

1 interaction

Monitor/Modify Tx

quizartinib + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfasalazine
Vanflyta (quizartinib)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

quizartinib + sulfasalazine

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• teplizumab
Vanflyta (quizartinib)

+

teplizumab

1 interaction

Monitor/Modify Tx

quizartinib + teplizumab

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• teriflunomide
Vanflyta (quizartinib)

+

teriflunomide

1 interaction

Monitor/Modify Tx

quizartinib + teriflunomide

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• thalidomide
Vanflyta (quizartinib)

+

thalidomide

1 interaction

Monitor/Modify Tx

quizartinib + thalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tocilizumab
Vanflyta (quizartinib)

+

tocilizumab

1 interaction

Monitor/Modify Tx

quizartinib + tocilizumab

monitor CBC: combo may decr. quizartinib levels, efficacy; may incr. risk of serious infection, myelosuppression (hepatic metab. altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• tofacitinib
Vanflyta (quizartinib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

quizartinib + tofacitinib

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• trimethoprim
Vanflyta (quizartinib)

+

trimethoprim

1 interaction

Monitor/Modify Tx

quizartinib + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• upadacitinib
Vanflyta (quizartinib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

quizartinib + upadacitinib

monitor CBC: combo may incr. risk of serious infection, myelosuppression (additive effects)

• valproic acid
Vanflyta (quizartinib)

+

valproic acid

1 interaction

Monitor/Modify Tx

quizartinib + valproic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• verapamil
Vanflyta (quizartinib)

+

verapamil

1 interaction

Monitor/Modify Tx

quizartinib + verapamil

monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited)

• zidovudine
Vanflyta (quizartinib)

+

zidovudine

1 interaction

Monitor/Modify Tx

quizartinib + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)